Core Viewpoint - Tuo Yun Biotechnology (01332) experienced a significant drop of over 60% in its stock price, nearly erasing gains made since late October of the previous year [1] Group 1: Stock Performance - As of the latest update, Tuo Yun's stock price fell by 60%, trading at HKD 0.104, with a trading volume of HKD 85.13 million [1] - The stock's decline is attributed to shareholder activities, including the deposit of shares into Mingji Securities, valued at HKD 36.58 million, representing 5.85% of the total [1] - Additionally, a transfer of shares from Wutong Securities to KGI Securities Asia occurred, with a value of HKD 35.35 million, accounting for 5.04% [1] Group 2: Company Overview - Tuo Yun Biotechnology's primary business includes providing QR codes and solutions for product packaging, manufacturing and selling packaging products, securities investment and trading, lending, and producing and selling Rhizoclonium, microalgae, and related products [1] - For the mid-year results of 2025, the company reported revenue of HKD 36.58 million from goods and services, reflecting a year-on-year decrease of 20.82% [1] - The company achieved a profit attributable to shareholders of HKD 11.24 million, marking a turnaround from a loss to profitability year-on-year [1]

Core Viewpoint - Tuo Yun Bio (01332) experienced a significant drop of over 60% in its stock price, nearly erasing gains made since late October last year [1] Group 1: Stock Performance - As of the report, Tuo Yun Bio's stock price fell to 0.104 HKD, with a trading volume of 85.13 million HKD [1] - The stock's decline is attributed to shareholder activities, including the deposit of shares into Mingji Securities, valued at 36.58 million HKD, representing 5.85% of the total [1] - A transfer of shares from Wutong Securities to KGI Securities Asia occurred, with a value of 35.35 million HKD, accounting for 5.04% [1] Group 2: Company Financials - Tuo Yun Bio's mid-year results for 2025 showed a revenue of 36.58 million HKD from goods and services, reflecting a year-on-year decrease of 20.82% [1] - The company reported a profit attributable to owners of 11.24 million HKD, marking a turnaround from a loss [1] Group 3: Business Overview - Tuo Yun Bio's primary business includes providing QR codes and solutions for product packaging, manufacturing and selling packaging products, securities investment and trading, lending, and producing and selling Rhizoclonium, microalgae, and related products [1]

Core Viewpoint - The article highlights the strategic developments of Tuo Yun Biotechnology (透云生物), including significant stock movements and new business partnerships aimed at expanding its market presence in the algae product sector [1]. Group 1: Stock and Shareholder Information - On January 15, Tuo Yun Biotechnology's shareholders deposited stocks into Mingji Securities, with a total market value of HKD 36.5841 million, representing 5.85% of the company [1]. Group 2: Strategic Partnerships - Tuo Yun's wholly-owned subsidiary, Shanxi Tuo Yun, signed a strategic cooperation agreement on October 23 with Shenzhen Building Supply Chain Technology, Henan Guozi Marketing Management, and Beijing He Wan Jia Biotechnology, committing to procure no less than RMB 1 billion worth of Rhine algae and related products from 2026 to 2028 [1]. Group 3: Product Development and Market Expansion - In November 2024, Tuo Yun's Rhine algae received new usage approval from the National Health Commission, allowing the company to expand its applications and enter markets for artificial fish, shrimp, and plant-based milk [1].